Figure 3

Pharmacokinetics. (A) Serum clearance of TF2 determined by ELISA in cohorts 1, 2, and 4 that received 75 mg of TF2, and in cohort 3, 150 mg (mean±standard deviation; N=5 per cohort). TF2 cleared rapidly from the serum, with cohort 3 having twice as high serum concentrations. (B) ¹¹¹In-IMP288 blood clearance per cohort (mean±standard deviation; N=5 per cohort). In all cohorts, >98% ID was cleared at 24 h p.i., although peptide blood clearance was somewhat delayed by shortening the interval between bsMAb and peptide administration, and to a lesser extent due to a higher antibody and a lower peptide doses.